Beth mae “Clir” yn ei olygu?
Nid yw'r anifail yn cario'r treiglad. Ni fydd yn datblygu'r afiechyd ac ni fydd yn ei drosglwyddo.
Ci Dirywiad System Lluosog Canine Yn Kerry Blue Terrier (CMSD-KBT)
The Canine Multiple System Degeneration (CMSD) DNA test is essential for Kerry Blue Terrier owners to ensure their dogs' health. CMSD is a hereditary neurological disorder affecting coordination and movement in Kerry Blue Terriers. Early genetic testing helps identify carriers and affected dogs, enabling responsible breeding decisions. By using the CMSD DNA test, breeders can reduce the risk of passing this debilitating condition to future generations. This test provides accurate, reliable results, promoting the well-being of your Kerry Blue Terrier. Protect your dog’s health with the CMSD DNA test today. Regular screening supports a healthier, happier canine companion.
Talfyriad: CMSD-KBT
Treiglad wedi'i ddadansoddi : SERAC1 c.1536G>A
Etifeddiaeth: Autosomal Reciliol
Acronym
CMSD-KBT
Amlder a arsylwyd
Difrifoldeb clinigol
Dosbarthiad clinigol
Clefydau Niwrolegol
Treiglad wedi'i ddadansoddi
SERAC1 c.1536G>A
p.(Trp512*)
p.(Trp512*)
Modd etifeddiaeth
Autosomal Reciliol
Crynodeb prawf:
Canine Multiple System Degeneration (CMSD) is a genetic disorder affecting Kerry Blue Terriers, causing progressive neurological decline. A DNA test is available to identify carriers and affected dogs, helping breeders make informed decisions. Early detection through testing can prevent the spread of this debilitating condition within the breed. Responsible breeding practices rely on these genetic insights to maintain healthy Kerry Blue Terrier populations. Overall, the CMSD DNA test is a valuable tool for canine health management.
Ar gael o'r pecyn: Basic
Mae'r prawf DNA hwn wedi'i gynnwys gan ddechrau o'n pecyn Basic - ac mae hefyd yn rhan o'r pecynnau Basic, Standard, Advanced, Complete.
Gweld Pecynnau Prawf DNA →Dewiswch y pecyn sy'n gweddu orau i'ch strategaeth bridio neu iechyd eich anifeiliaid.
Understanding Canine Multiple System Degeneration in Kerry Blue Terriers (CMSD-KBT)
Canine Multiple System Degeneration (CMSD) is a progressive neurological disorder that primarily affects Kerry Blue Terriers. This condition is characterized by the degeneration of multiple systems within the nervous system, leading to a range of debilitating symptoms that can significantly impact the quality of life of affected dogs.
Symptoms of CMSD-KBT
The symptoms of CMSD-KBT typically manifest in early to mid-adulthood, although the age of onset can vary. Common signs include balance problems, difficulty walking, and a general lack of coordination. As the disease progresses, affected dogs may exhibit muscle weakness, tremors, and a decline in overall mobility. In some cases, dogs may also experience changes in behavior, such as increased anxiety or a reluctance to engage in normal activities.
Pathophysiology of CMSD-KBT
The underlying cause of CMSD-KBT lies in genetic mutations that affect the nervous system's ability to function properly. These mutations lead to the degeneration of nerve cells, which in turn causes a breakdown of communication between the brain and the body. This disruption results in the clinical symptoms observed in affected dogs. Understanding the genetic basis of CMSD-KBT is crucial for breeders and owners, as it allows for informed decisions regarding breeding practices and the management of affected animals.
Management and Care for Affected Dogs
While there is currently no cure for CMSD-KBT, management strategies can help improve the quality of life for affected dogs. Regular veterinary check-ups are essential for monitoring the progression of the disease and addressing any health concerns that arise. Physical therapy and rehabilitation exercises can assist in maintaining mobility and strength. Additionally, providing a safe and supportive environment can help dogs cope with their symptoms and enhance their overall well-being.
Casgliad
Canine Multiple System Degeneration in Kerry Blue Terriers is a serious condition that requires attention from dog owners and breeders. By understanding the symptoms, underlying causes, and management strategies associated with CMSD-KBT, stakeholders can work towards improving the lives of affected dogs while making informed breeding decisions to reduce the prevalence of this condition in the breed.
Brid yn cael ei gydnabod ar gyfer y prawf: Dirywiad System Lluosog Canine Yn Kerry Blue Terrier (CMSD-KBT)
- Kerry Blue Terrier
🧬 Interpretation of genotypes CMSD-KBT
Genoteip
Statws
🟡 N/N
Heb fod yn gludwr - Dim Risg
🟡 N/CMSD-KBT
Cludwr - Dim Risg
❌ CMSD-KBT/CMSD-KBT
Wedi'i Effeithio - Mewn Perygl
FAQ: deall y dehongliad
Ydy “Cludwr” yn ddifrifol?
Mae'r anifail yn gyffredinol iach ond gall drosglwyddo'r treiglad iddo epil.
Beth os yw anifail yn cael ei “Effeithio”?
Mae'n cario dau gopi treigledig. Disgwylir arwyddion clinigol yn dibynnu ar y clefyd. Ni ddylid ei fridio.
Pam mae gwahaniaethau rhwng gwryw / benyw?
Mae rhai afiechydon yn gysylltiedig â rhyw, felly mae eu mynegiant yn amrywio yn dibynnu ar y rhyw anifail.
Rhagfynegi Epil
N/N (heb-fod-yn-gludwr)
N/CMSD-KBT (Cludwr)
CMSD-KBT/CMSD-KBT (Wedi'i effeithio)
Cwestiynau Cyffredin Prawf DNA
Beth mae'r prawf DNA hwn yn ei ganfod?
This DNA test detects the mutation associated with Canine Multiple System Degeneration In Kerry Blue Terrier (CMSD-KBT) in order to identify clear, carrier, or at-risk animals.
Pam rhoi prawf ar anifail magu?
Mae profion DNA yn helpu bridwyr i gynllunio paru mwy diogel a lleihau'r risg o drosglwyddo'r mwtaniad i'r epil.
Beth yw modd etifeddiaeth y prawf hwn?
Y modd etifeddu a adroddwyd ar gyfer y prawf hwn yw Autosomal Recessive.
Pa dreiglad sy'n cael ei ddadansoddi yn y prawf hwn?
This test analyses the mutation SERAC1 c.1536G>A.
A effeithir ar anifail cludo o reidrwydd?
Ddim o reidrwydd. Mae dehongliad yn dibynnu ar y patrwm etifeddiaeth a'r genoteip canlyniadol.
Cyfeiriadau
Johnson GS, Mhlanga-Mutangadura T, Morava E, Kozicz T, Taylor JF, O’Brien DP, Schnabel RD. Canine Multiple System Degeneration is Associated with Distinct SERAC1 Mutations in Two Different Dog Breeds [abstract]. Presented at the 63rd Annual Meeting of the American Society of Human Genetics in Boston, Massachusetts; 2013 Oct 22-26.